Do analysts rate NSPR or HSAQ?

InspireMD presently has a consensus price target of $4.50, indicating a potential upside of 542.77%. Given InspireMD's stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, NSPR or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than InspireMD. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InspireMD $10.85M 3.02 -$19.92M -$0.73 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Which has preferable valuation & earnings, PETV or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than PetVivo. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PetVivo $1.05M 29.25 -$10.95M -$0.38 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Which has higher earnings & valuation, RVP or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Retractable Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Retractable Technologies $37.15M 0.58 -$7.01M -$0.21 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Which has stronger earnings & valuation, HSAQ or TMDIF?

Titan Medical has higher revenue and earnings than Health Sciences Acquisitions Co. 2. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A Titan Medical $17.63M 1.14 $6.95M $0.05 3.52

Is HSAQ or TMDIF more profitable?

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Titan Medical's return on equity. Company Net Margins Return on Equity Return on Assets Health Sciences Acquisitions Co. 2 N/A N/A -2.38% Titan Medical N/A -82.31% -51.47%

Which has preferable valuation and earnings, LMNX or HSAQ?

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Health Sciences Acquisitions Co. 2. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Defiance Daily Target 2X Long LMND ETF $437.66M 0.01 $15.17M $0.51 32.06 Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

$4.75 +0.51 (+12.03%)

As of 06/29/2026

Compare

HSAQ vs. NSPR, PETV, RVP, TMDIF, and LMNX

Should you buy Health Sciences Acquisitions Co. 2 stock or one of its competitors? MarketBeat compares Health Sciences Acquisitions Co. 2 with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Health Sciences Acquisitions Co. 2 include InspireMD (NSPR), PetVivo (PETV), Retractable Technologies (RVP), Titan Medical (TMDIF), and Defiance Daily Target 2X Long LMND ETF (LMNX). These companies are all part of the "medical" sector.

How does Health Sciences Acquisitions Co. 2 compare to InspireMD?

InspireMD (NYSE:NSPR) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

InspireMD presently has a consensus price target of $4.50, indicating a potential upside of 542.77%. Given InspireMD's stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

InspireMD has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than InspireMD.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.85M	3.02	-$19.92M	-$0.73	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

44.8% of InspireMD shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 29.7% of InspireMD shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, InspireMD's average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company	Overall Sentiment
InspireMD	Neutral
Health Sciences Acquisitions Co. 2	Neutral

Summary

InspireMD beats Health Sciences Acquisitions Co. 2 on 6 of the 11 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to PetVivo?

PetVivo (NASDAQ:PETV) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, PetVivo had 6 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 6 mentions for PetVivo and 0 mentions for Health Sciences Acquisitions Co. 2. PetVivo's average media sentiment score of 0.17 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that PetVivo is being referred to more favorably in the media.

Company	Overall Sentiment
PetVivo	Neutral
Health Sciences Acquisitions Co. 2	Neutral

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

PetVivo has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than PetVivo.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	29.25	-$10.95M	-$0.38	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 10.8% of PetVivo shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Health Sciences Acquisitions Co. 2 beats PetVivo on 6 of the 10 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Retractable Technologies had 1 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 1 mentions for Retractable Technologies and 0 mentions for Health Sciences Acquisitions Co. 2. Retractable Technologies' average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company	Overall Sentiment
Retractable Technologies	Neutral
Health Sciences Acquisitions Co. 2	Neutral

Retractable Technologies has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Retractable Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Retractable Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$37.15M	0.58	-$7.01M	-$0.21	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

Summary

Health Sciences Acquisitions Co. 2 beats Retractable Technologies on 5 of the 9 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Titan Medical?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Comparatively, 0.0% of Titan Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Titan Medical has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A
Titan Medical	$17.63M	1.14	$6.95M	$0.05	3.52

In the previous week, Health Sciences Acquisitions Co. 2's average media sentiment score of 0.00 equaled Titan Medical'saverage media sentiment score.

Company	Overall Sentiment
Health Sciences Acquisitions Co. 2	Neutral
Titan Medical	Neutral

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Titan Medical	N/A	-82.31%	-51.47%

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Summary

Health Sciences Acquisitions Co. 2 beats Titan Medical on 4 of the 7 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Defiance Daily Target 2X Long LMND ETF?

Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF	$437.66M	0.01	$15.17M	$0.51	32.06
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

Defiance Daily Target 2X Long LMND ETF has a beta of 7.56, meaning that its stock price is 656% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

In the previous week, Defiance Daily Target 2X Long LMND ETF had 5 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 5 mentions for Defiance Daily Target 2X Long LMND ETF and 0 mentions for Health Sciences Acquisitions Co. 2. Defiance Daily Target 2X Long LMND ETF's average media sentiment score of 0.18 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Defiance Daily Target 2X Long LMND ETF is being referred to more favorably in the media.

Company	Overall Sentiment
Defiance Daily Target 2X Long LMND ETF	Neutral
Health Sciences Acquisitions Co. 2	Neutral

87.8% of Defiance Daily Target 2X Long LMND ETF shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Health Sciences Acquisitions Co. 2's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Summary

Defiance Daily Target 2X Long LMND ETF beats Health Sciences Acquisitions Co. 2 on 8 of the 10 factors compared between the two stocks.

Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSAQ vs. The Competition

Export

Metric	Health Sciences Acquisitions Co. 2	Surgical & medical instruments Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.26M	$49.99M	$7.07B	$12.45B
Dividend Yield	N/A	1.08%	2.66%	6.16%
P/E Ratio	N/A	19.29	27.25	24.87
Price / Sales	N/A	33.28	540.68	102.84
Price / Cash	N/A	18.87	48.53	58.59
Price / Book	-7.66	9.09	11.01	6.54
Net Income	-$380K	-$16.99M	$3.57B	$336.70M
7 Day Performance	17.57%	8.54%	2.31%	2.88%
1 Month Performance	21.48%	1.23%	1.39%	0.64%
1 Year Performance	77.24%	-1.70%	36.71%	31.34%

Health Sciences Acquisitions Co. 2 Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSAQ Health Sciences Acquisitions Co. 2	N/A	$4.75 +12.0%	N/A	+70.9%	$53.26M	N/A	N/A	4	High Trading Volume
NSPR InspireMD	3.5226 of 5 stars	$0.70 -0.1%	$4.50 +542.8%	-69.2%	$32.79M	$10.85M	N/A	50	Gap Up
PETV PetVivo	N/A	$0.83 +0.6%	N/A	+5.0%	$30.23M	$1.05M	N/A	20
RVP Retractable Technologies	N/A	$0.72 +4.8%	N/A	+12.6%	$21.56M	$37.15M	N/A	240	News Coverage
TMDIF Titan Medical	N/A	$0.16 -1.2%	N/A	-38.5%	$18.44M	$17.63M	N/A	50	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSAQ) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

HSAQ vs. NSPR, PETV, RVP, TMDIF, and LMNX

How does Health Sciences Acquisitions Co. 2 compare to InspireMD?

Summary

How does Health Sciences Acquisitions Co. 2 compare to PetVivo?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Retractable Technologies?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Titan Medical?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Defiance Daily Target 2X Long LMND ETF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSAQ vs. The Competition

Health Sciences Acquisitions Co. 2 Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

HSAQ vs. NSPR, PETV, RVP, TMDIF, and LMNX

How does Health Sciences Acquisitions Co. 2 compare to InspireMD?

Do analysts rate NSPR or HSAQ?

Which has more risk and volatility, NSPR or HSAQ?

Which has preferable earnings and valuation, NSPR or HSAQ?

Is NSPR or HSAQ more profitable?

Do insiders & institutionals believe in NSPR or HSAQ?

Does the media favor NSPR or HSAQ?

Summary

How does Health Sciences Acquisitions Co. 2 compare to PetVivo?

Does the media prefer PETV or HSAQ?

Is PETV or HSAQ more profitable?

Which has more volatility and risk, PETV or HSAQ?

Which has preferable valuation & earnings, PETV or HSAQ?

Do insiders and institutionals hold more shares of PETV or HSAQ?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Retractable Technologies?

Do institutionals and insiders have more ownership in RVP or HSAQ?

Does the media refer more to RVP or HSAQ?

Which has more risk & volatility, RVP or HSAQ?

Is RVP or HSAQ more profitable?

Which has higher earnings & valuation, RVP or HSAQ?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Titan Medical?

Do insiders and institutionals have more ownership in HSAQ or TMDIF?

Which has stronger earnings & valuation, HSAQ or TMDIF?

Does the media refer more to HSAQ or TMDIF?

Is HSAQ or TMDIF more profitable?

Which has more volatility and risk, HSAQ or TMDIF?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Defiance Daily Target 2X Long LMND ETF?

Which has preferable valuation and earnings, LMNX or HSAQ?

Which has more risk & volatility, LMNX or HSAQ?

Does the media prefer LMNX or HSAQ?

Do insiders & institutionals have more ownership in LMNX or HSAQ?

Is LMNX or HSAQ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSAQ vs. The Competition

Health Sciences Acquisitions Co. 2 Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools